Microgynon 21 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol / Levonorgestrel, the active ingredient in Microgynon 21, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 150 µg levonorgestrel oral tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age.

GNH USA supplies Microgynon 21 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon 21, a combined oral contraceptive, is used to manage reproductive hormone pathways.

- Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. - Treatment of acne: can improve hormonal acne by reducing androgenic activity.

Common Side Effects: - Nausea: mild to moderate stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: occasional tension‑type or migraine‑like headaches. - Breakthrough bleeding: spotting between periods, often resolves with continued use. - Weight gain: slight fluid retention reported by some users. - Mood changes: mild fluctuations in mood or irritability.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Arterial thrombosis: stroke or myocardial infarction, particularly in high‑risk individuals. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or abnormal liver enzymes. - Hypertension: significant rise in blood pressure.

Before prescribing Microgynon 21, clinicians should evaluate individual risk factors and contraindications.

- Contraindications: known or suspected pregnancy, active thromboembolic disease, estrogen‑dependent tumor, uncontrolled hypertension, severe liver disease. - Smoking: avoid use in women over 35 who smoke due to increased cardiovascular risk. - Medical history: assess cardiovascular, hepatic, and migraine history before initiation. - Drug interactions: review concomitant medications that may reduce efficacy or increase hormone levels. - Pregnancy and lactation: not recommended; discuss alternative methods with patients. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Microgynon 21 may interact with several medicines that alter hormone metabolism or efficacy.

Major Interactions (Avoid): - Potent enzyme inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive effectiveness. - Antifungal azoles (e.g., ketoconazole): can increase hormone concentrations, raising the risk of side effects. - Protease inhibitors (certain antiretrovirals): may alter hormone metabolism and affect efficacy.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may affect bleeding patterns. - St. John’s wort and other herbal supplements: can lower contraceptive reliability. - Diuretics: may exacerbate hypertension or electrolyte disturbances.